A Delaware judge has dismissed a request from GSK Plc (NYSE:GSK) and other pharmaceutical companies to appeal a ruling that allows over 70,000 lawsuits alleging the heartburn drug Zantac causes cancer ...
How do you explain one Zantac manufacturer kiboshing a favorable trend of defense verdicts and decisions – with a massive $2.2 billion settlement? The answer appears to lie with the whistleblower suit ...
Investors and analysts are only now starting to pay serious attention to GSK's potential historical liabilities relating to Zantac (ranitidine). GSK has been named as a defendant in approximately ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback